Article:Mycobacterium africanum--review of an important cause of human tuberculosis in West Africa (2946903)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q21144526. Its title is Mycobacterium africanum--review of an important cause of human tuberculosis in West Africa and the publication date was 2010-09-28. The initial author is Bouke C. de Jong.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: PLoS Neglected Tropical Diseases

Mycobacterium africanum—Review of an Important Cause of Human Tuberculosis in West Africa

  • Bouke C. de Jong
  • Martin Antonio
  • Sebastien Gagneux

[1]MRC Laboratories, Bacterial Diseases Programme, Fajara, The Gambia

[2]New York University Division of Infectious Diseases, New York, New York, United States of America

[3]Institute for Tropical Medicine, Mycobacteriology Unit, Antwerp, Belgium

[4]MRC National Institute for Medical Research, London, United Kingdom

[5]Swiss Tropical and Public Health Institute, Basel, Switzerland

  • Mathieu Picardeau (Editor)

Institut Pasteur, France

Publication date (collection): 9/2010

Publication date (epub): 9/2010

Abstract

Mycobacterium africanum consists of two phylogenetically distinct lineages within the Mycobacterium tuberculosis complex, known as M. africanum West African 1 and M. africanum West African 2. These lineages are restricted to West Africa, where they cause up to half of human pulmonary tuberculosis. In this review we discuss the definition of M. africanum, describe the prevalence and restricted geographical distribution of M. africanum West African 1 and 2, review the occurrence of M. africanum in animals, and summarize the phenotypic differences described thus far between M. africanum and M. tuberculosis sensu stricto.

Paper

Introduction

Mycobacterium africanum causes up to half of human tuberculosis (TB) in West Africa [1],[2]. It was first described as a distinct sub-species within the Mycobacterium tuberculosis complex (MTBC) by Castets and colleagues in 1968 [3]. M. africanum yields variable results on classical biochemical characterization, which has complicated the proper classification of the sub-species. This classification has been revised since the advent of molecular genotyping techniques (Figure 1) [4]. Thus, M. africanum type I (West African clade) has recently been sub-divided into M. africanum type I, West African 1 (MAF1), prevalent around the Gulf of Guinea, and M. africanum type I, West African 2 (MAF2), prevalent in western West Africa [5] (Figure 1). The M. africanum type II (East African clade) has been reclassified into M. tuberculosis sensu stricto (Figure 1) [4], and is indicated as “Uganda” genotype in Figure 2. Castets wrote a French review on M. africanum in 1979 [6]. While both M. africanum type I and type II were previously reviewed by Onipede and colleagues [7], this review focuses on the two West African lineages within M. africanum type I, MAF1 and MAF2. We use the term “M. africanum” when referencing studies in which no molecular distinction between MAF1 and MAF2 was included or when MAF1 and MAF2 were described together.

10.1371/journal.pntd.0000744.g001Figure 1

Biochemical classification is reviewed in Table 1. LSPs, large sequence polymorphisms [5]. Spoligotype signatures are reviewed in [16].

10.1371/journal.pntd.0000744.g002Figure 2

The position of M. africanum in the global phylogeny of the M. tuberculosis complex (MTBC) as originally published by Hershberg et al.[23].

This phylogeny is based on over 65 kb of DNA sequence data (89 concatenated gene sequences) in each of 108 strains of the MTBC and was inferred using maximum parsimony, which resulted in a single tree with negligable homoplasy [23]. Analysis by the neighbor-joining method resulted in an identical tree topology with high statistical support for all main branches [23]. This phylogeny has been referred to as the most robust and most detailed phylogeny of the MTBC to date, and thus should be considered as the new gold standard for classification of the MTBC [87]. The six main MTBC lineages adapted to humans and the animal strains are indicated in different colors. The human MTBC lineages include four M. tuberculosis lineages and the two M. africanum type I lineages. The “Uganda” genotype (formally referred to as M. africanum type II), which is a sub-lineage within M. tuberculosis lineage 4 (also known as the Euro-American lineage), is also shown. These lineages are completely congruent to previous classifications based on LSPs [15], [23], [78]. Black arrows indicate genomic regions or regions of difference (RDs) that are deleted in all descendent strains belonging to a particular lineage or sub-lineage. The scale indicates the genetic distance as number of SNPs (adapted from Figure 1 in [23] with additional data from [5]).

Methods

We searched PubMed, Web of Knowledge, and Embase databases using the terms “Mycobacterium africanum” and “M. africanum”, and identified further references in these articles.

Results

Definition of M. africanum

In 1968 in Dakar, Senegal, Castets and colleagues reported mycobacterial strains that, in biochemical testing, were intermediaries between M. tuberculosis and Mycobacterium bovis, and named these mycobacteria Mycobacterium africanum[3]. Like M. tuberculosis, M. africanum strains were found to be sensitive to pyrazinamide. However, like M. bovis, M. africanum tended to be nitrate negative, a weak producer of niacin, and to grow microaerophilically in media supplemented with pyruvate, albeit with variable results (Table 1, [8]). Meissner described similar isolates from Ghana in 1969 [9]. On Lowenstein-Jensen solid agar, M. africanum grew more slowly than M. tuberculosis, with cultures occasionally yielding growth only after 10 weeks, compared to 3–4 weeks in M. tuberculosis[10], [11]. Castets thus recommended a 90-day incubation for isolation of M. africanum[6]. In minimal media using glucose as sole carbon source, M. africanum could not use L-alanine as sole nitrogen source, similar to M. bovis[12]. Using colony morphology and biochemical results, a distinction was made between the Dakar variety of M. africanum, which likely corresponds to MAF2, and a Yaounde variety, which likely corresponds to MAF1, as well as a Rwanda variety that may have corresponded with the former East African M. africanum type II (i.e., today's Uganda genotype of M. tuberculosis) [13], [14]. However, studies based on molecular typing have shown that M. africanum isolates can exhibit a whole range of biochemical phenotypes [4], which complicates unambiguous classification based on phenotypic testing. By contrast, molecular-based taxonomy is more reliable if appropriate molecular markers are used. Based on the traditional genotyping tools used for routine molecular epidemiological investigation (i.e., IS6110 RFLP and spoligotype analysis), M. africanum exhibits a few characteristics that, however, are not always diagnostic [15]. For example, spoligotype patterns tend to permit unambiguous classification, lacking spacers 8 through 12 and 37 through 39 in MAF1 and spacers 7 through 9 and 39 in MAF2 [2], [16].

10.1371/journal.pntd.0000744.t001Table 1

Classification of M. africanum Relative to M. tuberculosis and M. bovis.

Characteristic M. africanum Type I M. tuberculosis M. bovis Reference
West African 1 West African 2
Morphological [3]
Colony appearance Dysgonic Dysgonic Eugonic Dysgonic
Depth of growth Microaerophilic Microaerophilic Aerophilic Microaerophilic
Biochemical [1], [13], [17]
Nitrate reductase Negative to weakly positive Negative to weakly positive Present Absent
Niacin production Negative to weakly positive Negative to weakly positive Present Absent
Drug susceptibility [3]
Pyrazinamide (PZA) Sensitive Sensitive Sensitive Resistant
Thiophene-2-carboxylic acid hydrazide (TCH) Sensitive Sensitive Resistant Sensitive
Molecular
Large sequence polymorphisms RD711 RD702 [4], [5]
SNPs—see Table S1 [23]
Spoligotype analysis AFRI 2 & 3; absence of spacers 8–12 & 37–39 AFRI 1; absence of spacers 7–9 & 39 Absence of spacer 34 Absence of spacers 39–43 [16]
IS6110 RFLP Average of 10 bands Average of 5 bands [17], [18]

However, for strains that lack the MAF1- or MAF2-specific spacers as well as spacers 33–36, additional molecular tests are required for classification, as such spoligotype patterns could also indicate Euro-American M. tuberculosis. Members of MAF1 typically show more than five IS6110 copies and MAF2 generally harbors five or fewer IS6110 copies [17], [18]. The completion of the first M. tuberculosis genome sequence facilitated the development of a mycobacterial classification system based on genomic deletions or large sequence polymorphisms (LSPs) [19]. Because the MTBC has a clonal population structure with essentially no horizontal gene exchange, genomic deletions are irreversible and hence represent robust phylogenetic markers. The presence or absence of particular genomic regions of difference can be used to define specific lineages within the MTBC [20]. Following such an approach, initial studies established that MAF1 and MAF2 are distinct lineages, with MAF1 sharing the RD9 deletion with MAF2 and M. bovis, while MAF2 and M. bovis share additional deletions of RD7, RD8, and RD10 (Figure 2) [21], [22]. These studies also demonstrated that M. africanum type II is in fact a member of M. tuberculosis sensu stricto as it contains the TbD1 deletion, which is a characteristic marker for a subset of M. tuberculosis (Figure 2) [21]. Subsequent studies in which M. africanum DNA was compared to M. tuberculosis H37Rv using comparative genome hybridization identified additional LSPs that are specific to MAF1 (RD711) and to MAF2 (RD702; Table 1) [4], [5].

Recently, a large-scale multilocus sequence analysis identified multiple single nucleotide polymorphisms (SNPs) specific to MAF1, MAF2, and former M. africanum type II (Figure 2, Table S1) [23]. These SNPs can thus be used to define these M. africanum lineages unambiguously [15]. The study by Hershberg and colleagues [23] also highlights the large genetic distance that separates MAF1 and MAF2 when compared with other lineages within the MTBC (Figure 2). This high genetic diversity might lead to important phenotypic differences among and between MAF1 and MAF2.

Several other genotyping screens for differentiation of the various species of the MTBC have been developed, such as a PCR protocol in which MAF1 and MAF2 can be distinguished based on LSPs and SNPs [24]. A recent publication identified further polymorphisms specific for MAF1 and for MAF2, as well as two SNPs in rpoB that define sub-lineages within MAF2 [25]. However, the current commercial speciation tests do not distinguish between MAF1 and MAF2 (e.g., GenoType MTBC, Hain Lifescience, Germany).

Prevalence and Distribution of M. africanum

Paleopathological investigation using spoligotype analysis of human remains from Egypt's Middle Kingdom (c. 2000–1600 B.C.) identified MAF2 alongside M. tuberculosis[26], [27], although M. africanum has not been identified in North or East Africa since [28] and has never been identified in Southern Africa [29]. Studies in Senegal conducted in the 1970s showed that the prevalence of M. africanum in that country varied by region and averaged 21% among smear-positive pulmonary TB patients [30] (Table 2). Studies in other West African countries, using biochemical speciation, suggested a prevalence of M. africanum ranging from 31% in Mali and Burkina Faso to 66% in Benin [13]. Based on molecular genotyping results, the prevalence of MAF1 appears highest in Benin (39%) and Ghana (21%), with a distribution as shown in Figure 3. Interestingly, the prevalence of MAF1 may be declining in Cameroon; whereas 30 years ago 56% of TB was caused by M. africanum based on biochemical speciation [31], an M. africanum prevalence of only 9% was reported in a recent study using molecular methods [32]. The prevalence of MAF2 appears highest in Guinea Bissau, where 51% of smear-positive TB was caused by MAF2, based on spoligotyping patterns [1]. As shown in Figure 3, the distributions of MAF1 and MAF2 overlap in southern West Africa, particularly in Ghana [33] and Benin [34].

10.1371/journal.pntd.0000744.g003Figure 3

M. africanum prevalence in Western African countries.

Prevalence figures were derived from the most recently published studies from Table 2 and unpublished data from Tunisia, Senegal, Cote d'Ivoire, Cameroon, and the Central African Republic extracted from the SITVIT2 proprietary database of Institut Pasteur de la Guadeloupe. If studies did not list the prevalence of MAF1 and/or MAF2, the estimates were based on interpretation of the spoligotype patterns. Areas with MAF1 are shaded in brown and areas with MAF2 are shaded in green, with striped shading if prevalence of MAF1 and MAF2 exceeds 5% each. Map courtesy of http://www.theodora.com/maps/, used with permission.

10.1371/journal.pntd.0000744.t002Table 2

Prevalence of M. africanum in Different West African Countries.

Country n West African 1 (MAF1) West African 2 (MAF2) M. africanumb Year Reference
Benin 152 93 (66%) 1982 [13]
Benin 194 55 (39%) 13 (9%) 2005–2006 2009a[34]
Burkina Faso 102 17 (18%) 1979 [52]
Burkina Faso 80 25 (31%) 1982 [13]
Burkina Faso 378 (18%) 1992–1994 1996 [79]
Burkina Faso 120 0 2 (1.7%) 2007a[80]
Cameroon (56%) 1971 [31]
Cameroon 455 40 (9%) 0 1997–1998 2003 [32]
The Gambia 359 0 138 (38%) 2002–2006 2009 [2]
Ghana 99 42 (42%) 1989 [81]
Ghana 64 13 (20%) 2003 2007 [82]
Ghana 1921 8.4% 21% 2001–2004 2008 [49]
Guinea Bissau 229 0 117 (51%) 1999a[1]
Mali 203 66 (33%) 1973 1974 [11]
Mali 214 66 (31%) 1982 [13]
Mali 119 2 (1.7%) 33 (28%) 2006–2008 2009 [54]
Niger 178 81 (46%) 1982 [13]
Nigeria 55 human; 17 cattle 6 (11%) human; 1 (5.9%) cattle 0 2006 [60]
Senegal 69 7 (10%) 1994–1995 1999a[83]
Sierra Leone 441 122 (28%) 1992–1993 1997 [84]
Sierra Leone 97 17 (18%) 2003–2004 2008 [85]
a

Estimates based on interpretation of signature spoligotype patterns in this reference.

b

As defined by biochemical criteria.

M. africanum has sporadically been identified in areas outside of the West African region, including Germany [9], [35], [36], England [37], California [38], France [39], and Spain [40], both from pulmonary and extra-pulmonary sources. Case reports describe extra-pulmonary TB caused by M. africanum as disseminated disease [41], cutaneous disease [42], orchiepididymitis [40], prostatitis [43], pleural disease [44], bone disease [45], brain mass [46], and proctitis [47]. However, in most cases, TB patients carrying M. africanum were immigrants from West Africa. The only confirmed outbreak of M. africanum outside of West Africa occurred in France, where isolates from the first outbreak of multi-drug-resistant (MDR) TB, diagnosed during the period 1989 to 1992, were initially identified as M. bovis on the basis of phenotypic tests. However, later genotypic analysis identified spoligotype patterns consistent with MAF1. The index case in this outbreak originated from Brazil [18], although no MAF1 or MAF2 isolates have been identified in Brazil [48].

Other studies comparing drug resistance have yielded variable results: In Ghana, no difference in drug resistance was identified between M. africanum and M. tuberculosis[49], whereas a previous regional survey identified more primary resistance among M. africanum isolates [13]. The Yaounde variant of M. africanum (corresponding to MAF1) may have higher rates of primary resistance to thiacetazone [50][52]. This former first-line anti-tuberculous drug has largely been replaced by rifampicin, because of a higher incidence of side effects, particularly in patients with HIV [53]. A recent abstract reported lower drug resistance among MAF2 isolates from Mali relative to M. tuberculosis[54].

Animal Connection of M. africanum

The proximity of MAF2 to the animal isolates on the phylogenetic tree of the MTBC (Figure 2) raises the possibility of an animal reservoir for MAF2. Extensive studies in Senegal in the 1970s screened cows, sheep, and pigs, as well as soil samples, but did not identify any non-human reservoir for M. africanum infection [30]. Neither M. bovis nor other mycobacteria were detected in these animals. Similarly, a recent extensive search for bovine TB in The Gambia, Senegal, Guinea Bissau, and Guinea neither identified tuberculin skin test–positive cows, nor abattoir samples suggestive of TB [55]. An abattoir survey among sheep and goats in The Gambia did not yield any evidence for mycobacterial disease either [56].

M. africanum has sporadically been isolated from animals; it has been cultured from monkeys from Central and West Africa with active TB [57], from monkeys in a French veterinary laboratory [58], from four cows from the same dairy farm in Bangladesh that were thought to be infected by a caretaker (MAF2, all with a shared spoligotype pattern, [59]), and twice from a cow in Nigeria (MAF1 [60], M. africanum[61]). M. africanum can become widely distributed within the tissues of infected animals, and meat or milk may be a route of exposure to M. africanum for humans [62]. Efficient human-to-human transmission of MAF2 by aerosol is, however, suggested by the fact that human contacts sleeping in the same bedroom as MAF2 patients have higher rates of tuberculin skin test positivity than contacts sleeping in a different bedroom, with a similar gradient to the one seen with exposure to M. tuberculosis[63]. Close interaction between humans and monkeys is limited in West Africa, and it is unclear whether monkeys form a reservoir for M. africanum infection, or whether they were themselves infected by humans or a third animal species.

Experimental Work on M. africanum

A study in cows found that M. africanum, unlike M. tuberculosis, was equally pathogenic as M. bovis[62]. Other animal studies have yielded mixed results, possibly due to differences between the two lineages of M. africanum. When infecting guinea pigs with M. africanum isolates from Dakar (likely MAF2), virulence, as measured by the relative weight of the spleen, was lower for M. africanum than for the laboratory strain M. tuberculosis H37Rv. The histopathologic lesions observed in the liver resembled those seen after infection with M. bovis Bacillus Calmette-Guérin (BCG), with the absence of caseation [64]. Using isolates from Ghana (where MAF1 is more prevalent than MAF2), M. africanum was found to be equally virulent as M. tuberculosis in guinea pigs, but avirulent in rabbits [9]. Isolates from Central Africa (MAF1 or M. tuberculosis) were found to be equally virulent in rabbits compared with M. tuberculosis[65]. Tuberculin skin tests, using purified protein derivative (PPD) derived from the respective organisms as well as from Mycobacterium avium, showed cross-reaction between M. tuberculosis and M. africanum PPD both in humans and in animals [66], [67].

In a recent study, BALB/c and C57BL/6 mice were infected with different clinical MAF2 isolates by intravenous tail vein infection and by intra-tracheal aerosol, and bacterial replication in spleen and lungs was compared to infection with M. tuberculosis H37Rv (K. Huygen, unpublished data). Significant differences in growth were observed between MAF2 isolates: some isolates displayed the same virulence as M. tuberculosis reflected by increasing numbers of CFU in lungs, while other MAF2 isolates showed an attenuated phenotype with little colonization of the lungs. These findings suggest that phenotypic differences exist within the lineage of MAF2 in mouse models, which may in turn explain the variable results in guinea pigs and rabbits.

Clinical and Epidemiological Differences between M. africanum and M. tuberculosis

In The Gambia, where we identified M. africanum (exclusively MAF2) in sputa of 38% of smear-positive TB patients, we identified various clinical and epidemiological differences between MAF2 and M. tuberculosis[68], [69]. In a recent multivariable analysis, we compared patients infected with MAF2 (n = 289) relative to the Euro-American lineage of M. tuberculosis (EAMTB, n = 403), which represent 90% of M. tuberculosis sensu stricto isolates in The Gambia [70]. We found that TB patients infected with MAF2 were more likely to be older, to be HIV infected, and to be severely malnourished (Table 3). MAF2 patients were more likely to have more than half the lung fields involved on chest X-ray, despite a similar duration of cough. There was no difference in the proportion of patients with a BCG scar between the two organisms. MAF2 patients were less likely to produce IFNγ in an ESAT-6/CFP-10 ELISPOT assay (OR 0.32, 95% CI 0.18–0.59, p<0.0001), although results of tuberculin skin testing were similar [63]. Similarly, MAF2-exposed household contacts were less likely to respond to ESAT-6 in an IFNγ ELISPOT assay than were those exposed to M. tuberculosis[63]. Transmission of MAF2 from TB patients to their household contacts occurred at the same rate as that of M. tuberculosis, as measured by the tuberculin skin test at baseline and at 3 months, yet household contacts exposed to MAF2 were less likely to develop TB disease in the next 2 years than were contacts exposed to M. tuberculosis[71]. The mortality on TB treatment in HIV-negative TB patients was similar between the two organisms, around 3% [69]. The association with HIV infection and the lower progression to disease in HIV-negative patients suggest that MAF2 is somewhat attenuated compared to M. tuberculosis. The older age of MAF2 patients may reflect the lower rate of progression to disease. The lower rate of IFNγ responses against ESAT-6 by TB cases infected with MAF2 and their exposed contacts may result from defective ESAT-6 secretion, consistent with preliminary results of ESAT-6 immunoblots of culture filtrates of MAF2 and M. tuberculosis. It is unclear whether this ESAT-6 secretion defect results from the fact that the Rv3879c gene in the RD1 region is non-functional in MAF2 [63]. In a Mycobacterium marinum model, Rv3879c was found to be essential for ESAT-6 but not CFP-10 secretion [72]. However, an M. bovis BCG recombinant strain with a deletion of Rv3878 to Rv3881 efficiently secreted the ESAT-6 and CFP-10 antigens. Similarly, a clinical M. tuberculosis isolate lacking Rv3878 and Rv3879c was found to secrete both ESAT-6 and CFP-10 [73], and an M. bovis null mutant of the Rv3879c homolog was not attenuated for growth in guinea pigs [74]. More work is needed to elucidate the molecular basis of the lower ESAT-6 response in TB patients and their household contacts infected with M. africanum.

10.1371/journal.pntd.0000744.t003Table 3

Epidemiological, Clinical, and Immunological Differences of M. africanum Relative to M. tuberculosis.

Characteristic Country M. africanum OR(95% CI) p-Value Reference
West African 1 West African 2
Molecular clustering (IS6110 RFLP) Ghana Lower 0.38(0.3–0.5) <0.001 [49]
Progression to disease in first two years after exposure The Gambia Lower 3.1(1.1–8.7) 0.036 [71]
Prevalence of HIV co-infection The Gambia Higher 2.13(1.2–3.8) 0.010 [68][86]
Ghana Same as MTB NS [49]
IFNγ response to ESAT-6 The Gambia Lower 0.32(0.18–0.59) 0.0001 [63], [86]
Age The Gambia Older 2.0(1.3–2.9) 0.001 [86]
Ghana Same as MTB NS [49]
Chest X-ray involvement The Gambia Worse 1.6(1.1–2.1) 0.005 [86]
Ghana Less lower lobe disease in HIV-negative patients 0.34(0.2–0.6) <0.001 [49]

Underlined text indicates results from the study from Ghana, which combined the West African 1 and 2 data.

Italic text indicates results from the study from The Gambia, which only identified West African 2.

CI, confidence interval; ESAT-6, early secreted antigen- 6 kDa; IS6110 RFLP, insertion sequence 6110 restriction fragment length polymorphisms; MTB, M. tuberculosis.

Studying nearly 2,000 TB patients from Ghana, 29% of whom were infected with M. africanum (MAF1 and MAF2 combined) as opposed to M. tuberculosis, no differences in the rates of HIV co-infection, nor chest X-ray severity, were seen between these organisms [49]. HIV-negative M. tuberculosis patients were significantly more likely to have exclusively lower zone disease on chest X-ray. Chest X-rays did not differ between MAF1 and MAF2. M. africanum patients were significantly less likely to have recently transmitted disease (i.e., be part of a transmission cluster) as opposed to reactivation disease. A lower clustering rate in M. africanum compared to M. tuberculosis is consistent with the lower progression to disease observed in The Gambia.

Similar to early findings in Dakar [6], we observed a longer time to growth in culture of MAF2 relative to M. tuberculosis on primary isolation from sputum, both in liquid and solid medium, adjusted for the degree of smear positivity and extent of disease on chest X-ray (p<0.0001, B. de Jong, unpublished data).

Unanswered Questions

The reason why M. africanum has not established itself outside of the West Africa region remains enigmatic. Potential explanations for the limited geographic spread of M. africanum despite massive migrations of West Africans to the Americas at the time of the slave trade include the possibility that diseased slaves did not survive the crossing of the Atlantic, or that M. africanum did initially establish itself in the New World, but was subsequently outcompeted by M. tuberculosis, possibly due to its lower rate of progression to disease relative to M. tuberculosis. Moreover, M. africanum may not have established itself in the indigenous American people and in their European colonizers if this organism has a host preference for ethnically West African persons. Indeed, a recent study described a host polymorphism found in Ghana that is associated with protection against Euro-American M. tuberculosis, yet not against M. africanum, and may thus have provided a selective advantage for M. africanum in West African populations [75]. Studies of innate immune responses in individuals of different ethnic origins could test the hypothesis that M. africanum has adapted to preferentially establishing infection in West African hosts [5].

A West African animal reservoir of MAF2 that sustains a large reservoir of latent infection in humans, and maintains MAF2 in the human population despite a lower rate of progression, would be in line with the phylogenetic relatedness of MAF2 and the animal strains within the MTBC. A larger reservoir of latent infection of MAF2 in The Gambia could in turn explain the association with HIV infection seen in that country, yet not in Ghana. However, a putative animal reservoir is more difficult to invoke for MAF1 given that this lineage is phylogenetically more distant from the classical animal-adapted sub-species of the MTBC (Figure 2).

As DNA extraction from organisms causing latent infection is impossible with the currently available technologies, we need new tools to distinguish between latent infections with different sub-species within the MTBC. We found that antigens from the TbD1 region, present in M. africanum but absent from M. tuberculosis, failed to induce a T cell response that could be measured in an IFNγ ELISPOT [76]. Availability of the whole genome sequence of a strain of MAF2 [77] will facilitate identification of other potentially differential T cell and B cell epitopes. Establishing such tools would allow us to compare the size of the reservoir of latent infection with M. africanum relative to M. tuberculosis, and to answer whether MAF2, with its lower rate of progression to disease, protects against progression to disease of M. tuberculosis. Such a protection could explain why MAF2, with its lower rate of progression and shared host, has not been out-competed by M. tuberculosis.

Understanding the genotypic differences underlying the phenotypic differences between MAF2 and M. tuberculosis can greatly enhance our understanding of TB pathogenesis. To this end, the completion of the MAF2 whole genome sequence will facilitate experimental studies on the biological differences between MAF2 and M. tuberculosis, such as candidate genes that may underlie the attenuated ESAT-6 response induced by MAF2. In addition, more research should be dedicated to MAF1, as little is known on putative phenotypic characteristics of this M. africanum lineage. To successfully address all of these research questions, a comprehensive and multidisciplinary “systems epidemiology” approach will be necessary [78].

In conclusion, MAF 1 and MAF 2 are phylogenetically “ancient” sub-species within the MTBC that show phenotypic differences relative to M. tuberculosis (as observed for MAF2 in The Gambia), and may be gradually outcompeted by M. tuberculosis (as suggested for MAF1 in Cameroon). Studies on MAF2 can inform on TB pathogenesis, as MAF2, if defective ESAT-6 secretion is confirmed, could provide a model for the effects of ESAT-6 in the natural human host. Conversely, the lower progression to disease of MAF2 makes this organism a potential model for the study of containment of TB. Lastly, the new generations of TB diagnostics and vaccines currently under development need to ensure efficacy in M. africanum–endemic areas.

Learning Points

M. africanum is a sub-species of the M. tuberculosis complex that consists of two distinct lineages, West African 1 and 2

Unambiguous identification of M. africanum requires molecular methods

M. africanum is found only in West Africa, where it causes up to half of human TB

M. africanum West African 2 has distinct phenotypes compared to M. tuberculosis, such as a lower progression to disease in exposed contacts, despite a similar rate of transmission

Infection with M. africanum responds to regular TB treatment

Key Papers

Castets M, Boisvert H, Grumbach F, Brunel M, Rist N (1968) [Tuberculosis bacilli of the African type: preliminary note]. Rev Tuberc Pneumol (Paris) 32: 179–184.

Mostowy S, Onipede A, Gagneux S, Niemann S, Kremer K, et al. (2004) Genomic analysis distinguishes Mycobacterium africanum. J Clin Microbiol 42: 3594–3599.

de Jong BC, Hill PC, Brookes RH, Gagneux S, Jeffries DJ, et al. (2006) Mycobacterium africanum elicits an attenuated T cell response to early secreted antigenic target, 6 kDa, in patients with tuberculosis and their household contacts. J Infect Dis 193: 1279–1286.

Meyer CG, Scarisbrick G, Niemann S, Browne EN, Chinbuah MA, et al. (2008) Pulmonary tuberculosis: virulence of Mycobacterium africanum and relevance in HIV co-infection. Tuberculosis (Edinb) 88: 482–489.

de Jong BC, Hill PC, Aiken A, Awine T, Antonio M, et al. (2008) Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J Infect Dis 198: 1037–1043.

Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S, et al. (2008) High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol 6: e311. doi:10.1371/journal.pbio.0060311.

Supporting Information

Table S1

Single nucleotide polymorphisms (SNPs) that define the various M. africanum lineages, based on [23] and [15].

(0.07 MB DOC)

Click here for additional data file.

Acknowledgements

The authors thank Aileen McCrillis for assistance with the literature search and Nalin Rastogi and Thierry Zozio (Institut Pasteur de la Guadeloupe) for providing the MAF1 and MAF2 prevalence data from the SITVIT2 proprietary database, as well as for interpretation of spoligotype patterns from published work. Experiments on mice were conducted using protocols approved by the ethical committee on animal care and use (CODA-PIB-WIV, number 060202-02).

References

  1. G KalleniusT KoivulaS GhebremichaelSE HoffnerR Norberg1999Evolution and clonal traits of Mycobacterium tuberculosis complex in Guinea-Bissau.J Clin Microbiol373872387810565899
  2. BC de JongM AntonioT AwineK OgungbemiYP de Jong2009Use of spoligotyping and large-sequence polymorphisms to study the population structure of the Mycobacterium tuberculosis complex in a cohort study of consecutive smear positive tuberculosis cases in the Gambia.J Clin Microbiol
  3. M CastetsH BoisvertF GrumbachM BrunelN Rist1968[Tuberculosis bacilli of the African type: preliminary note].Rev Tuberc Pneumol (Paris)321791844985104
  4. S MostowyA OnipedeS GagneuxS NiemannK Kremer2004Genomic analysis distinguishes Mycobacterium africanum.J Clin Microbiol423594359915297503
  5. S GagneuxK DeRiemerT VanM Kato-MaedaBC de Jong2006Variable host-pathogen compatibility in Mycobacterium tuberculosis.Proc Natl Acad Sci U S A1032869287316477032
  6. M Castets1979[Mycobacterium africanum (author's transl)].Med Trop (Mars)3914514891078
  7. AO OnipedeBC de JongRA Adegbola2005Mycobacterium africanum- a review.African Journal of Clinical and Experimental Microbiology6167175
  8. SR PattynF PortaelsL SpanogheJ Magos1970Further studies on African strains of Mycobacterium tuberculosis: comparison with M. bovis and M. microti.Ann Soc Belges Med Trop Parasitol Mycol502112274996738
  9. G MeissnerK Schroder1969[The so-called African mycobacteria strains from the tropical West Africa].Zentralbl Bakteriol Orig21169814989345
  10. J GrossetG DecroixC Sors1971[Tuberculosis due to Mycobacterium africanum in African negroes in the Paris area].Rev Tuberc Pneumol (Paris)354304365002286
  11. J GrossetS SangareN RistL Meyer1974Cultural and Biochemical Characteristics of Tubercle Bacilli Isolated From 230 Cases of Tuberculosis in Mali.Bull Int Union Tuberc49177187
  12. G Van Der GroenSR Pattyn1975Comparison of Mycobacterium africanum, M. tuberculosis and M. bovis by their utilization of carbon and nitrogen sources.Ann Soc Belg Med Trop55647651821405
  13. IM Toure1982[The status of Mycobacterium africanum in West Africa].Bull Int Union Tuberc572412496820295
  14. HL DavidMT JahanA JuminJ GrandryHE Lehman1978Numerical Taxonomy Analysis of Mycobacterium africanum.International Journal of Systematic Bacteriology28467472
  15. I ComasS HomolkaS NiemannS Gagneux2009Genotyping of genetically monomorphic bacteria: DNA sequencing in mycobacterium tuberculosis highlights the limitations of current methodologies.PLoS ONE4e7815doi:10.1371/journal.pone.000781519915672
  16. EM StreicherTC VictorG van der SpuyC SolaN Rastogi2007Spoligotype signatures in the Mycobacterium tuberculosis complex.J Clin Microbiol4523724017065260
  17. R FrothinghamPL StricklandG BretzelS RamaswamyJM Musser1999Phenotypic and genotypic characterization of Mycobacterium africanum isolates from West Africa.J Clin Microbiol371921192610325347
  18. C Viana-NieroC GutierrezC SolaI FilliolF Boulahbal2001Genetic diversity of Mycobacterium africanum clinical isolates based on IS6110-restriction fragment length polymorphism analysis, spoligotyping, and variable number of tandem DNA repeats.J Clin Microbiol39576511136749
  19. AG TsolakiAE HirshK DeRiemerJA EncisoMZ Wong2004Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from genomic deletions in 100 strains.Proc Natl Acad Sci U S A1014865487015024109
  20. S GagneuxPM Small2007Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development.Lancet Infect Dis732833717448936
  21. R BroschSV GordonM MarmiesseP BrodinC Buchrieser2002A new evolutionary scenario for the Mycobacterium tuberculosis complex.Proc Natl Acad Sci U S A993684368911891304
  22. S MostowyD CousinsJ BrinkmanA AranazMA Behr2002Genomic deletions suggest a phylogeny for the Mycobacterium tuberculosis complex.J Infect Dis186748012089664
  23. R HershbergM LipatovPM SmallH ShefferS Niemann2008High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography.PLoS Biol6e311doi:10.1371/journal.pbio.006031119090620
  24. RC HuardM FabreP de HaasLC LazzariniD van Soolingen2006Novel genetic polymorphisms that further delineate the phylogeny of the Mycobacterium tuberculosis complex.J Bacteriol1884271428716740934
  25. SE Goncalves VasconcellosRC HuardS NiemannK KremerAR Santos2010Distinct genotypic profiles of the two major clades of Mycobacterium africanum.BMC Infect Dis108020350321
  26. AG NerlichS Losch2009Paleopathology of human tuberculosis and the potential role of climate.Interdiscip Perspect Infect Dis200943718719360109
  27. AR ZinkC SolaU ReischlW GrabnerN Rastogi2003Characterization of Mycobacterium tuberculosis complex DNAs from Egyptian mummies by spoligotyping.J Clin Microbiol4135936712517873
  28. SR PattynW KeterewAG HadguL Van Den Breen1978Identification and drug sensitivity of tubercle bacilli from Addis Ababa, Ethiopia.Ann Soc Belg Med Trop58596298117
  29. AM DemersS MostowyD CoetzeeR WarrenP van Helden2010Mycobacterium africanum is not a major cause of human tuberculosis in Cape Town, South Africa.Tuberculosis (Edinb)
  30. S DiopD de MedeirosG de MedeirosR BayletM Sankale1976[Incidence and geographic distribution of Mycobacterium africanum in Senegal].Bull Soc Med Afr Noire Lang Fr2150561000739
  31. M HuetN RistG BoubeD Potier1971[Bacteriological study of tuberculosis in Cameroon].Rev Tuberc Pneumol (Paris)354134265002285
  32. SN Niobe-EyangohC KuabanP SorlinP CuninJ Thonnon2003Genetic biodiversity of Mycobacterium tuberculosis complex strains from patients with pulmonary tuberculosis in Cameroon.J Clin Microbiol412547255312791879
  33. M GoyalS LawnB AffulJW AcheampongG Griffin1999Spoligotyping in molecular epidemiology of tuberculosis in Ghana.J Infect3817117510424797
  34. D AffolabiG AnyoF FaihunN SanoussiIC Shamputa2009First molecular epidemiological study of tuberculosis in Benin.Int J Tuberc Lung Dis1331732219275790
  35. H JungbluthH FinkF Reusch1978[Tuberculous infection caused by Myco. africanum in black africans resident in the German Federal Republic (author's transl)].Prax Klin Pneumol32306309662812
  36. KH Schroder1982[Occurence of M. africanum in the Federal Republic of Germany (author's transl)].Zentralbl Bakteriol Mikrobiol Hyg [A]251341344
  37. JM GrangeMD Yates1989Incidence and nature of human tuberculosis due to Mycobacterium africanum in South-East England: 1977-87.Epidemiol Infect1031271322789145
  38. E DesmondAT AhmedWS ProbertJ ElyY Jang2004Mycobacterium africanum cases, California.Emerg Infect Dis1092192315200832
  39. J FrottierM EliaszewiczV ArletC Gaudillat1990[Infections caused by Mycobacterium africanum].Bull Acad Natl Med17429–33; discussion 34252190671
  40. I Perez-de PedroP BermudezI ArteroMS Jimenez2008[Orchiepididymitis due to Mycobacterium africanum].Enferm Infecc Microbiol Clin2660060219100186
  41. J ReparazAS OlivanMA PinillosJ UrizMJ Lopez-Unzu1987[Disseminated Mycobacterium africanum infection].Rev Med Univ Navarra311031053671954
  42. L BarilE CaumesC Truffot-PernotF BricaireJ Grosset1995Tuberculosis caused by Mycobacterium africanum associated with involvement of the upper and lower respiratory tract, skin, and mucosa.Clin Infect Dis216536558527560
  43. MA Remacha EsterasI Parra ParraMD Blanco Mercade2003[Disseminated tuberculosis due to Mycobacterium africanum].Arch Bronconeumol39376
  44. MJ AldeaMA LezcanoA EstebanS BelloM Vila1990[Pleuropulmonary tuberculosis caused by Mycobacterium africanum in a white male].Enferm Infecc Microbiol Clin864652095912
  45. JC PetitD Lesage1980Bone tuberculosis due to Mycobacterium africanum- 2 cases.Nouvelle Presse Medicale92845
  46. N BhanotO BademL MathewM Haran2008Mycobacterium africanum Presenting as a Brain Mass.Infect Dis Clin Pract16327329
  47. M JanierL Wagner1987Ulcerative tuberculosis of the anal canal due to Mycobacterium africanum.Annales De Dermatologie Et De Venereologie11413951397
  48. K BrudeyJR DriscollL RigoutsWM ProdingerA Gori2006Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology.BMC Microbiol62316519816
  49. CG MeyerG ScarisbrickS NiemannEN BrowneMA Chinbuah2008Pulmonary tuberculosis: virulence of Mycobacterium africanum and relevance in HIV co-infection.Tuberculosis (Edinb)8848248918590979
  50. R BercionC Kuaban1997Initial resistance to antituberculosis drugs in Yaounde, Cameroon in 1995.Int J Tuberc Lung Dis11101149441073
  51. G AbateT KoivulaSE Hoffner2002In vitro activity of thiacetazone on mycobacterial species belonging to the Mycobacterium tuberculosis complex.Int J Tuberc Lung Dis693393512365582
  52. JL ReyA VillonM MenardG Le MaoJP Albert1979[Present state of resistance to antibiotics by tuberculous bacilli in Africa (author's transl)].Med Trop (Mars)3914915491079
  53. P NunnD KibugaS GathuaR BrindleA Imalingat1991Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis.Lancet3376276301705647
  54. B DiarraA TounkaraB TraoreM MaigaS Diallo2009Molecular Identification of Drug Resistant Mycobacteria Species in Bamako, Mali.Keystone Conference: Overcoming the Crisis of TB and AIDS (T2)Arusha, Tanzania
  55. F UngerS MünstermannA GoumouCN ApiaM Konte2003Risk associated with Mycobacterium bovis infections detected in selected study herds and slaughter cattle in 4 countries of West Africa.BanjulITC (International Trypanotolerance Centre)125
  56. B GoossensS OsaerS KoraKJ ChandlerL Petrie1998Abattoir survey of sheep and goats in The Gambia.Vet Rec1422772819569483
  57. MF Thorel1980Isolation of Mycobacterium africanum from monkeys.Tubercle611011046776671
  58. MF Thorel1980[Mycobacteria identified in a centre for veterinary research between 1973 and 1979 (author's transl)].Ann Microbiol (Paris)13161696767431
  59. Z RahimM MollersA te Koppele-VijeJ de BeerK Zaman2007Characterization of Mycobacterium africanum subtype I among cows in a dairy farm in Bangladesh using spoligotyping.Southeast Asian J Trop Med Public Health3870671317883011
  60. S CadmusS PalmerM OkkerJ DaleK Gover2006Molecular analysis of human and bovine tubercle bacilli from a local setting in Nigeria.J Clin Microbiol44293416390943
  61. SI CadmusMK YakubuAA MagajiAO JenkinsD van Soolingen2010Mycobacterium bovis, but also M. africanum present in raw milk of pastoral cattle in north-central Nigeria.Trop Anim Health Prod
  62. IN de KantorJ PereiraJ MiquetR Rovere1979Pouvoir pathogene experimental de Mycobacterium africanum pour les bovins.Bull Acad Vet de France52499503
  63. BC de JongPC HillRH BrookesS GagneuxDJ Jeffries2006Mycobacterium africanum Elicits an Attenuated T Cell Response to Early Secreted Antigenic Target, 6 kDa, in Patients with Tuberculosis and Their Household Contacts.J Infect Dis1931279128616586366
  64. M CastetsH Sarrat1969[Experimental study of the virulence of Mycobacterium africanum (preliminary note)].Bull Soc Med Afr Noire Lang Fr146936965407132
  65. T KorsakM Millet1970[Observations on 200 strains of mycobacteria collected in Central Africa].Acta Tuberc Pneumol Belg613883984995307
  66. IN de KantorJA BarcatA Cetrangolo1979[M. africanum: experimental virulence and sensitizing capacity to different tuberculin PPDs (proceedings)].Bull Int Union Tuberc54173174526648
  67. D de MedeirosS DiopG de MedeirosR BayletM Sankale1974[Comparative allergological study of Mycobacterium tuberculosis of the classical type and Mycobacterium tuberculosis var. Africanum (apropos of 400 intradermoreactions)].Bull Soc Med Afr Noire Lang Fr19961044219597
  68. BC de JongPC HillRH BrookesJK OtuKL Peterson2005Mycobacterium africanum: a new opportunistic pathogen in HIV infection?AIDS191714171516184053
  69. BC de JongPC HillA AikenDJ JeffriesA Onipede2007Clinical presentation and outcome of tuberculosis patients infected by M. africanum versus M. tuberculosis.Int J Tuberc Lung Dis1145045617394693
  70. BC de JongI AdetifaB WaltherPC HillM Antonio2009Differences between TB cases infected with M. africanum, West-African type 2, relative to Euro-American M. tuberculosis- an update.FEMS Immunol Med Microbiol in press
  71. BC de JongPC HillA AikenT AwineM Antonio2008Progression to Active Tuberculosis, but Not Transmission, Varies by Mycobacterium tuberculosis Lineage in The Gambia.J Infect Dis1981037104318702608
  72. LY GaoS GuoB McLaughlinH MorisakiJN Engel2004A mycobacterial virulence gene cluster extending RD1 is required for cytolysis, bacterial spreading and ESAT-6 secretion.Mol Microbiol531677169315341647
  73. AS PymP BrodinL MajlessiR BroschC Demangel2003Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.Nat Med953353912692540
  74. J InwaldK JahansRG HewinsonSV Gordon2003Inactivation of the Mycobacterium bovis homologue of the polymorphic RD1 gene Rv3879c (Mb3909c) does not affect virulence.Tuberculosis (Edinb)8338739314623170
  75. CD IntemannT ThyeS NiemannEN BrowneM Amanua Chinbuah2009Autophagy gene variant IRGM -261T contributes to protection from tuberculosis caused by Mycobacterium tuberculosis but not by M. africanum strains.PLoS Pathog5e1000577doi:10.1371/journal.ppat.100057719750224
  76. BC de JongA HammondJK OtuM AntonioRA Adegbola2010Immunogenicity of antigens from the TbD1 region present in M. africanum and missing from “modern” M. tuberculosis: a cross- sectional study.BMC Infect Dis101120085647
  77. J Parkhill2010Mycobacterium genomes. Wellcome Trust Sanger Institute. Available: http://www.sanger.ac.uk/sequencing/Mycobacterium/africanum/
  78. I ComasS Gagneux2009The past and future of tuberculosis research.PLoS Pathog5e1000600doi:10.1371/journal.ppat.100060019855821
  79. S LedruB CauchoixM YameogoA ZoubgaJ Lamande-Chiron1996Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso.Tuber Lung Dis774294368959147
  80. S GodreuilG TorreaD TerruF ChevenetS Diagbouga2007First molecular epidemiology study of Mycobacterium tuberculosis in Burkina Faso.J Clin Microbiol4592192717251410
  81. TS van der WerfDG GroothuisB van Klingeren1989High initial drug resistance in pulmonary tuberculosis in Ghana.Tubercle702492552516670
  82. K AddoK Owusu-DarkoD Yeboah-ManuP CaulleyM Minamikawa2007Mycobacterial species causing pulmonary tuberculosis at the korle bu teaching hospital, accra, ghana.Ghana Med J41525717925842
  83. MN NiangYG de la SalmoniereA SambAA HaneMF Cisse1999Characterization of M. tuberculosis strains from west African patients by spoligotyping.Microbes Infect11189119210580274
  84. WH HaasG BretzelB AmthorK SchilkeG Krommes1997Comparison of DNA fingerprint patterns of isolates of Mycobacterium africanum from east and west Africa.J Clin Microbiol356636669041408
  85. S HomolkaE PostB OberhauserAG GeorgeL Westman2008High genetic diversity among Mycobacterium tuberculosis complex strains from Sierra Leone.BMC Microbiol810318578864
  86. BC de JongI AdetifaB WaltherPC HillM Antonio2010Differences between tuberculosis cases infected with Mycobacterium africanum, West African type 2, relative to Euro-American Mycobacterium tuberculosis: an update.FEMS Immunol Med Microbiol5810210520002176
  87. NH SmithRG HewinsonK KremerR BroschSV Gordon2009Myths and misconceptions: the origin and evolution of Mycobacterium tuberculosis.Nat Rev Microbiol753754419483712
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC2946903/fullTextXML. The license for the article is Creative Commons Attribution 2.5 Unported. The main subject has been identified as pulmonary tuberculosis.